Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who give their voluntary agreement to participate and sign a consent form
• Adults aged 18 to 75 years old, any gender
• People who have been confirmed through a tissue or cell sample to have limited-stage small cell lung cancer (a form where the cancer has not spread to distant parts of the body), with brain and bone scans completed before joining if there is any suspicion of spread to those areas
• People who have immunohistochemistry test results available (a specific type of laboratory test on tumour tissue — confirm with trial site)
• People whose planned chemotherapy includes either cisplatin or carboplatin, combined with etoposide
• People with a good general physical functioning level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
• People who weigh more than 40 kg
• People whose expected survival is at least 6 months
• People who have at least one measurable tumour site (not previously treated with radiotherapy) of 10 mm or larger as measured by CT or MRI scan
• People who have not previously received immunotherapy
• People whose blood, heart, lung, liver, and kidney test results fall within acceptable ranges as determined by the trial site (specific thresholds apply — confirm with trial site)
• Women who are either post-menopausal or who return a negative pregnancy test before joining

Who may not be able to join:

• People whose cancer has spread to distant organs (spread to lymph nodes above the collarbone may still be considered — confirm with trial site)
• People who have previously had radiotherapy to the chest area
• People who have a medical reason that prevents them from receiving etoposide combined with carboplatin or cisplatin chemotherapy
• People who have an active autoimmune disease, or a history of one (such as lung inflammation, eye inflammation, bowel inflammation, liver inflammation, or certain thyroid or kidney conditions), or who have used immune-suppressing medications in the past 28 days (some thyroid conditions that are well managed may still be considered — confirm with trial site)
• People who have previously received or are currently receiving a type of immunotherapy called PD-1 or PD-L1 therapy, or who are currently taking part in another interventional clinical trial
• People who have received other anti-cancer treatments, long-term immune or hormone therapies, or other experimental treatments within 4 weeks before the first dose in this trial
• People with serious uncontrolled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, or serious heart rhythm problems requiring treatment
• People with conditions affecting the immune system such as HIV, active hepatitis B or C, or active tuberculosis
• People who have had an active infection or unexplained fever above 38.5°C in the 2 weeks before screening (fevers caused by the tumour itself may be considered — confirm with trial site)
• People who, in the opinion of the trial team, have other serious medical, psychiatric, family, or social circumstances that could affect their safety or the reliability of trial data

Important: Always verify eligibility with the trial site directly before applying.